View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 15, 2022

Aural and Koneksa collaborate to use speech analytics for clinical trials

The partnership aims to easily incorporate speech measures to Koneksa studies and digital biomarker development programmes.

Speech neuroscience company Aural Analytics and patient-centric digital biomarker company Koneksa have entered a collaboration to support clinical trials using speech analytics.

Under the deal, Koneksa will further boost its platform and research expertise by leveraging Aural Analytics’ technology, Speech Vitals.

Speech is a key objective data stream that enables a better understanding of the progression of the disease and can be utilised to support new methods of care delivery in the at-home setting and clinic.

The existing state of neurology is mainly reliant on functional rating scales and patients’ self-reporting.

Aural’s Speech Vitals would add value on top of what currently existing tools offer so that clinicians can make improved decisions.

The research-grade platforms of the companies are streamlined to back trials at scale throughout development and commercial pharma pipelines.

Aural Analytics CEO Judy Smythe said: “Partnerships with leading digital research providers such as Koneksa strengthen our reach across the research ecosystem and advance our mission to develop best-in-class, clinical-grade speech analytics.

“Koneksa and Aural Analytics share a vision in which speech analytics are an essential element of best-in-class digital biomarkers, which, in time, will further the fields of research and clinical care across neurodegenerative conditions.”

The objective of this partnership is to easily incorporate speech measures into Koneksa studies and digital biomarker development programmes.

Koneksa CEO and co-founder Chris Benko said: “We’re excited to work with Aural Analytics to integrate speech collection in our clinical trials.

“Through this partnership, our teams will develop best-in-class digital biomarkers to pioneer a better care experience, with a particular focus on neurodegenerative conditions.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena